Skip to main content
. 2021 Dec 10;11(12):1347. doi: 10.3390/jpm11121347

Figure 7.

Figure 7

Representation of SD and EID groups in RRMS patients under Natalizumab treatment. Levels of (a) NTZ (μg/mL) and (b) sVCAM (pg/mL) in serum in the SD (n = 7) and EID (n = 14) groups. Each dot represents the concentration of NTZ or sVCAM in serum for each patient in the first extraction (V1). EID, extended interval dosing; NTZ, natalizumab; SD, standard dosing; sVCAM, soluble VCAM. ns: p > 0.05, * p < 0.05, **** p < 0.0001.